Solana

Solana Receivables

The Accounts Receivable of Solana (HSDT) as of Nov 5, 2026 is 70,000.00 USD. In the previous year, Accounts Receivable was 117,000.00 USD — a change of -40.17% (lower).

Receivables

70,000.00USD

YoY

-40.17%

Last updated:

Accounts Receivable of Solana is 2024 70,000.00 USD. Accounts Receivable of Solana was 2023 117,000.00 USD. It decreases by -40.17% lower compared to the previous year.

The Solana Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2017
700,000.00 USD
Jan 1, 2018
280,000.00 USD
Jan 1, 2019
210,000.00 USD
Jan 1, 2020
70,000.00 USD
Jan 1, 2021
70,000.00 USD
Jan 1, 2022
71,000.00 USD
Jan 1, 2023
117,000.00 USD
Jan 1, 2024
70,000.00 USD
The Solana Receivables history
YEARReceivablesYoY
70,000.00USD-40.17%
117,000.00USD+64.79%
71,000.00USD+1.43%
70,000.00USD0.00%
70,000.00USD-66.67%
210,000.00USD-25.00%
280,000.00USD-60.00%
700,000.00USD+204.35%
230,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Solana Stock analysis

What does Solana do? Helius Medical Technologies develops and markets the PoNS device, a portable neuromodulation stimulator for neurological wellness. The company focuses on non-invasive platform technologies that enhance the brain's healing ability. The PoNS device is authorized as a class II medical device in Canada for short-term treatment of chronic balance deficits caused by mild-to-moderate traumatic brain injury, used alongside physical therapy. It delivers non-invasive neurostimulation to the tongue to induce neuromodulation. Helius Medical Technologies targets healthcare providers and rehabilitation centers that treat patients with traumatic brain injury. The company's product is designed for use in clinical settings under professional guidance, specifically for patients requiring short-term balance deficit therapy. The PoNS device is positioned as a complementary treatment within physical therapy protocols for neurological rehabilitation. The firm's revenue model is based on the sale of the PoNS device to healthcare institutions and rehabilitation facilities. These institutions purchase the device for use in their treatment programs, leveraging its non-invasive neurostimulation technology to address balance deficits in patients with mild-to-moderate traumatic brain injury. The company's focus on neurological wellness through non-invasive solutions drives its commercial strategy. Solana is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Solana stock

Accounts Receivable of Solana is 70,000.00 USD in 2024.

Accounts Receivable of Solana changed from 117,000.00 USD to 70,000.00 USD, representing a -40.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Solana since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Solana historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Solana

All Key Metrics — Solana